Global Biomarkers Market Review
News Apr 14, 2016
Biomarkers are molecular or cellular diagnostic tools, measured in biological samples such as blood, saliva and urine. It is used as an indicator to measure and evaluate biological processes, pharmacological response and pathogenic processes. Some of the major types of biomarkers are prognostic, predictive, pharmacodynamic and efficacy response biomarker. A variety of biomarkers are available for biological systems such as immune system, cardiovascular system and metabolic system. Biomarkers are used to detect, predict disease susceptibility and monitor disease progression for infectious diseases, cancer, metabolic diseases, central nervous system disease and autoimmune diseases. Biomarker technologies have its applications in diagnosis and prognostic treatment for exposure of harmful chemicals, drug formulation and development and increasing implementation in disease diagnosis. Many drugs fail in clinical trials due to metabolism, toxicity, absorption, etc. Biomarkers are special tools usually used in clinical studies to determine the effects and desired results of drug in early stages of development. Biomarkers are cost effective and reliable for developing, monitoring and predicting efficiency of drugs.
North America dominates the global market of biomarkers due to increasing demand of aging population for diagnosis and treatment of age related diseases. In addition, higher adoption rate of biomarkers technologies is also driving the growth of biomarkers market in North America. Asia is expected to show high growth rates in the next five years in global biomarkers market. Some of the factors driving the growth of biomarkers market in emerging markets of Asia are increasing research and development activity in India and China, increasing number of contract research organizations and low cost for conducting clinical trials.
Growing importance of companion diagnostics and increasing demand of personalized medicine are some of the opportunities for global biomarkers market. However, ethical and regulatory issues, and early and accurate diagnosis for fatal diseases are some of the challenges for global biomarkers market. Government grants and initiatives for research and development of biomarkers are some of the trends for global biomarkers market. Some of the major companies operating in the global biomarkers market are Roche Diagnostic Limited, Siemens Healthcare, Abbott Laboratories Inc., Thermo Fisher Scientific, Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., Aushon BioSystem Inc., Epistem Ltd, G.E. Healthcare Inc., and Affymetrix, Inc.
Request Brochure of this Report: http://www.persistencemarketresearch.com/samples/2779
Key points covered in the report
- Report segments the market on the basis of types, application, products, technology, etc (as applicable)
The report covers geographic segmentation
- North America
- The report provides the market size and forecast for the different segments and geographies for the period of 2010 to 2020
- The report provides company profiles of some of the leading companies operating in the market
Blood Test To Determine When It Is Safe To Return To Play After A Sports-related ConcussionNews
A high-sensitive blood test can aid concussed hockey players when it might be safe to return to play. In a study published by the journal Neurology, researchers at Sahlgrenska Academy have identified a superior blood-based biomarker for assessing subtle brain injury.READ MORE
Putting Proteins in Their Proper PlaceNews
Everything in the cell has its right place. This includes certain molecules called RNA-binding proteins. When these are misplaced, they can end up causing dangerous clumps that are typical of diseases like ALS. A new study has found a way to send these proteins home.READ MORE
Stable Beta-Amyloid Dimers Identified in Alzheimer’s BrainsNews
A recent study exploited state-of-the-art mass spectrometry to provide the first direct evidence of beta-amyloid dimers in patients with Alzheimer’s disease and points to the potential of these molecules as biomarkers. Beta-amyloid dimers may be the smallest pathological species that trigger Alzheimer’s disease.
Comments | 0 ADD COMMENT
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018